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The management of patients with test icular germ cel l  tumours has changed
substantial ly since the late 1970s, largely because of the abi l i ty of cisplat in-based
polychemotherapy to cure patients with metastatic disease and also due to the
development of new strategies in tumour-reductive surgery and radiotherapy. Today,
more than 90 percent of patients with newly diagnosed testicular germ cell tumours
(seminoma or nonseminoma) are cured with avai lable treatment modali t ies. Further
progress in the management of testicular germ cell tumours could result from an
improved understanding of the epidemiology, biology and genetics of this uncommon
malignancy.
The present thesis describes several epidemiological aspects of testicular germ cell
tumours and focuses on the role of a genetic susceptibi l i ty of this malignant tumour. In
addit ion, the thesis addresses some relevant opics in the current management of
patients with stage I as well as metastatic nonseminomatous testicular germ cell
tumours (NSTGCT) and reviews the long-term outcome of patients with metastatic
NSTGCT treated at the Groningen University Hospital (GUH) in the past two decades.
The first section of Chapter I contains general information about testicular germ cell
tumours. Several epidemiological and aetiologic aspects, with particular attention to
observations uggesting a genetic predisposition to testicular germ cell tumours, are
discussed. Furthermore, the histological classification of the World Health
Organisation, cl inical presentation, diagnosis and the value of serum tumour markers
are described. Brief descriptions are given of the pattern of metastatic spread and
accurate staging methods, and an overview of various prognostic classification
systems including the classification system according to the International Germ Cell
Cancer Collaborative Group (IGCCCG) is presented. Moreover, the treatment and
prognosis of patients with stage I and metastatic testicular germ cell tumours are
discussed.
In the second section of Chapter 1 the aims and outline of the present thesis are
described.
Geographic variations in testicular cancer incidence may be caused by differences in
environmental factors, genetic factors, or both. Thus, information on geographic
patterns of occurrence may lead to more insight into the aetiology of testicular cancer,
which is stil l poorly understood. The aim of the study described in Chapter 2 was to
analyse geographic patterns of age-adjusted testicular cancer incidence rates (lRs) in
12 provinces in The Netherlands in the period 1989-1995. Moreover, the age-adjusted
lR of testicular cancer by degree of urbanisation was evaluated. Cancer incidence
data were retrieved from the files of the nation-wide population-based Netherlands
Cancer Registry.
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period 1989-1995 was 4.4 per 100,000 men. The province Groningen in the North
showed the highest annual lR with 5.8 per 100,000 men. This lR was higher than the
overal l  R in The Netherlands ( incidence rate rat io ( lRR) 1.3, 95o/o Cl 1. ' tr-1.6, P<0.05).
The highest lR in Groningen was seen for both seminomas and nonseminomas. l i -
addit ion, Groningen showed the highest age-specif ic lRs in al l  relevant younger age
groups (15-29, 3A-44, and 45-59 years), i l lustrat ing the consistency of data. The
province Friesland, also situated in the northern part of the country, showed the
second highest lR of test icular cancer with 5.3 cases per 100,000 men per year ( lRR
1.2, 95% Cl 1.0-1.5, not signif icant).  This mainly resulted from the high lR of
seminoma in Friesland.
Analysis of age-adjusted lRs of testicular cancer by degree of urbanisation in The
Netherlands showed no urban-rural differences at analysis of all histological types
combined, or at separate analyses of seminomas and nonseminomas.
It was concluded that geographic lustering of testicular cancer seems to be present in
the rural northern part of The Netherlands in areas with a stable founder population.
People in this founder population are likely to share a relatively high frequency of
genes from common ancestors including genes possibly related to testicular cancer.
Although this finding does not exclude the involvement of shared environmental
factors in the aetiology of testicular cancer, it may also lend support to a genetic
susceptibility to testicular cancer development. We hypothesised that testicular cancer
cases in stable founder populations eem particularly suitable for searching testicular
cancer susceptibility genes because such genes are likely to show increased
frequencies among affected men in founder populations.
The occurrence of bilateral testicular cancer (BTC) may also point to a role of genetic
factors in the aetiology of testicular cancer. However, development of second
contralateral testicular tumours is also influenced by systemic chemotherapy for the
first tumour. Chapter 3 describes the prevalence and prognosis of BTC in a large
single-centre population of 445 patients between 1967-1997 with initial stage I
disease, in which no systemic treatment was given after first orchidectomy. The
majority of stage I patients entered a surveillance study with an intensive follow-up
since 1982. We therefore hypothesised that after 1982, BTC was diagnosed at an
earlier stage of disease. The prevalence of BTC was 4.7Yo in a cohort of 170 stage I
patients treated between 1967-1981, and 2.9o/o in a cohort of 275 stage I patients
treated between 1982-1997 (not significant). ln the period 1967-1981, six patients had
stage I second tumours and two patients had stage lll second tumours. The former six
patients are alive with no evidence of disease and the two patients with metastatic
tumours died of disease or of treatment. In the period 1982-1997, all 8 patients had
stage I second tumours and all are alive with no evidence of disease.
The overall prevalence of BTC in stage I patients was 3.6% and has slightly
decreased over the past three decades. Patients developing a malignant tumour in
both testes may be considered at high risk of having a genetic predisposition to the
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disease. Furthermore, intensive follow-up, improvement of radiodiagnostic CT
techniques, avai labi l i ty of serum tumour markers, and patient education seem to have
resulted in earlier diagnosis and lower stage of contralateral testicular tumours,
contr ibuting to improved prognosis.
Familial occurrence of testicular cancer also suggests a genetic predisposition to the
disease. A genetic susceptibility may also be reflected by high rates of urogenital
developmental nomalies and BTC in famil ies prone to test icular cancer. ln Ghapter 4
the proportion of familial testicular cancer was analysed retrospectively in a single-
centre population of 693 testicular cancer patients treated between 1977-97 and the
relative risk (RR) for first-degree relatives of patients was estimated. In addition, the
existence of urogenital developmental nomalies and bi lateral test icular neoplasms in
famil ial  test icular cancer patients was evaluated.
Twenty-four of 693 patients (3.5%) had a first-degree relative with testicular cancer.
These 24 cases belonged to 17 families; in seven of these 17 families both affected
first-degree family members were part of the study population of 693 patients.
Consequently, the 693 studied patients belonged to a total of 686 famil ies. Thus, the
actual proport ion of famil ial  test icular cancer was 2.5% (17 of 686 famil ies). The
famil ial  cases consisted of 11 brother pairs, including two pairs of identical twins and
one pair which also had two affected cousins, and six father-son pairs (in total 36
cases, 12 treated elsewhere). Estimates of the RR to firstdegree relatives showed a
9- to 13-fold increased RR to brothers (P<0.001) and a 2-fold increased RR to fathers
(not significant) of testicular cancer patients. Among the 36 patients with familial
test icular cancer, two (5.6%) had BTC, four (1 1.1o/o) had undescended test is, three
(8.3%) had inguinal hernia, and one (2.8o/o) showed renal hypoplasia.
The present data on familial occurrence of testicular cancer may lend additional
support to a role of genetic factors in the aetiology of testicular cancer.
Current efforts in testicular cancer research have focused on developing treatment
regimens based on prognostic factor analysis in order to provide an accurate rísk-
adapted management of testicular cancer patients. Since stage of disease affects
treatment and prognosis, detailed information on stage distribution of testicular cancer
is necessary for planning this research. In Chapter 5 the stage distribution was
assessed using various classif icat ions, i .e. the Royal Marsden (RM), lndiana,
European Organisation for Research and Treatment of Cancer (EORTC), IGCCCG
and the Medical Research Counci l  (MRC), in 517 patients with NSTGCT treated at the
GUH between 1977-96.
The number of patients in four consecutive S-year periods (1977-81, 1982-86, 1987-
91 , 1992-96) was 1 19, 1 41, 141 , and 1 16, respectively. Frequency analyses howed a
significant increase of the number of RM stage l, in proportion to stage ll-lV, in 1982-
86 (55%, OR 2.54), 1987-91 (53o/o, OR 2.33) and 1992-96 (61%, OR 3.24) compared














































































disease showed a proport ionate signif icant decrease of the number of RM stage l l  in
1992-96 (29o/o, OR 0.43) compared with 1977-81 (49%). There was also a relative
decrease of good-prognosis patients with disseminated isease in 1992-96 compared
with 1977-81, using analyses of the Indiana (from 56% to 33o/o, OR 0.39) and EORTC
classification (from 78% to 560/0, OR 0.36). Analyses of the IGCCCG and MRU
classification showed a significant decrease in the percentage of good-prognosis
patients with metastatic disease in 1982-86 compared with the first 5-year period (for
IGCCCG, from 54%to35o/o, OR 0.46, and for MRC, from 43Toto24o/o, OR 0.42).
It was concluded that the stage distribution of NSTGCT over the past two decades has
changed. The proport ion of stage I patients has increased since the early 1980s,
apparently resulting from a shift of low-extent disseminated isease to stage I disease.
This f inding is relevant in reducing the treatment intensity required in a higher
proportion of patients and a subsequent reduction of long-term risk from treatment.
Today, the standard treatment for patients with clinical stage I NSTGCT is either
primary RPLND or close survei l lance with cisplat in-based polychemotherapy for
relapsing patients. Both treatment modali t ies produce an excel lent survival outcome
approaching 100%. Consequently, selection of the most appropriate treatment
strategy is not pre-eminently guided by survival considerations. In Ghapter 6 relevant
topics in the management of clinical stage I NSTGCT are reviewed to provide
information that wi l l  al low a rat ional select ion of the most appropriate management
option. The choice between the available options, each having its merits and its
drawbacks, should be made based on a number of factors including treatment-related
morbidity, views and expertise of the physician, patient preferences, the expected
degree of patient compliance, and prognostic factor analysis.
To date, the role of adjuvant chemotherapy as an alternative management option for
patients with cl inical stage I NSTGCT at high r isk of metastat ic disease is l imited and
needs further evaluation. This systemic adjuvant treatment modality would be a
realistic alternative if the reliability of prognostic factors to identify clinical stage I
patients at high risk of occult metastases could be improved. Reliable risk assessment
will facilitate an accurate risk-adapted management of the individual patient, with a
subsequent overall reduction of treatment-related morbidity.
The study described in Chapter 7 reviews chronological changes in the long-term
outcome of patients with metastatic NSTGCT treated at the GUH in the past two
decades. The 1O-year survival of prognostic subgroups according to various
prognostic classifications was examined in time to evaluate whether cumulative
experience has led to an improved outcome of patients with metastatic NSTGCT, and
to explore differences in outcome of prognostic subgroups.
Two hundred ninety-nine patients with metastatic NSTGCT who were treated with
cisplatin-based polychemotherapy during the period from 1977 to 1996 were
retrospectively staged according to RM classification and the following prognostic
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classifications: IGCCCG, Indiana, MRC and EORTC. The number of patients treated
between 1977-86 and 1987-96 was 146 and 153, respectively. Survival curves were
constructed using the Kaplan-Meier method and disease-specific 1O-year survival
rates of prognostic subgroups treated during the two consecutive 1O-year periods
were compared using the logrank test.
The median follow-up of surviving patients during the periods 1977-86 and 1987-96
were 14.7 years (range, 0.2-20.6 years) and 7.0 years (range, 0.4-11.4 years),
respectively. The actuarial disease-specific 1O-year survival rate of patients with
metastatic NSTGCT increased from 76Yo during the period 1977-86 to 88% during the
period 1987-96 (RR 0.51 ,95o/o Cl 0.29-0.89, P<0.05). The 10-year survival rates of
patients with good, intermediate and poor prognosis according to the IGCCCG
classification were 95o/o,74o/o, and 37o/o, respectively, during the period 1977-86 and
94o/o,87o/o, and 66%, respectively, during the period 1987-96. Patients with a poor
prognosis according to the IGCCCG classification showed the greatest increase in 10-
year survival (RR 0.43,95o/o Cl 0.18-1.04, P=0.06). Analysis using the RM, Indiana,
and EORTC classifications also showed an improved 10-year survival rate of patients
with a poor prognosis who were treated during 1987-96 compared with those who
were treated during 1977-86.
ln conclusion, the 1O-year survival rate of patients with metastatic NSTGCT who were
treated with cisplatin-based chemotherapy significantly increased from 760/o during the
period 1977-86 to 88% during the period 1987-96. This improvement during the
cisplatin era resulted mainly from an increase in the survival of patients with.metastatic
disease who had a poor prognosis. These results indicate that the management of
NSTGCT is stil l improving.
Following cisplatin-based polychemotherapy for metastatic NSTGCT, mature teratoma
is often found after resection of retroperitoneal residual tumour masses (RRTM).
Ghapter 8 describes the clinical course and outcome of patients after resection of
residual teratoma, with particular emphasis on patients relapsing with either growing
mature teratoma or secondary non-germ cell malignancy.
During the period 1979-95, 1 13 patients underwent a laparotomy for resection of
RRTM after chemotherapy for NSTGCT. Only patients with mature teratoma in the
RRTM were included in the present study, and data on the patients who experienced
a relapse were studied in detail. Mature teratoma was found in 51 patients (45.1o/o)
within RRTM resected after chemotherapy. Nine of these 51 patients (17.6To)
relapsed; the relapses resulted from growing mature teratoma in five patients (9.8%),
secondary non-germ cell malignancy in three patients (5.9%), and recurrent germ cell
malignancy in one patient (2.0%). In eight patients (15.7o/o), the recurrent disease
occurred after a disease free interval of at least two years after completion of cisplatin-
based polychemotherapy. The primary treatment for ail relapsing patients was surgical
resection. All five patients with growing mature teratoma are alive without evidence of
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patients with non-germ cel l  malignancy died of disease, and the remaining two areal ive with disease.
It was concluded that long-term follow-up after resection of postchemotherapy residualteratoma is indicated because a proportion of patients develop growing maturpteratoma or a secondary non-germ cell malignancy. The treatment for theserecurrences hould be aggressive, e.g. complete surgical resection.
In Ghapter 9 guidelines for further research are suggested. In addition, the results ofan extensive genotyping str-rdy of the HLA-region on chromosome 6 p21 in a largenumber of testicular cancer patients are described. This genotyping study performedat the GUH could not confirm the previously reported association between HLA classl l  genes and test icular germ cel l  tumours.
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